NCT02412267View on ClinicalTrials.gov

Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

December 31, 2015

Study Completion Date

March 31, 2016

Conditions
Diffuse Large B-cell Lymphoma
Interventions
DRUG

O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)

Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule

Trial Locations (1)

169610

National Cancer Centre, Singapore

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

National Cancer Centre, Singapore

OTHER

NCT02412267 - Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) | Biotech Hunter | Biotech Hunter